1	Safety	Safety	B-NP	NN	O	0	ROOT	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	verteporfin	verteporfin	B-NP	NN	O	2	PMOD	0
4	for	for	B-PP	IN	O	1	NMOD	0
5	treatment	treatment	B-NP	NN	O	4	PMOD	19	treatment
6	of	of	B-PP	IN	O	5	NMOD	0
7	subfoveal	subfoveal	B-NP	JJ	O	10	NMOD	0
8	choroidal	choroidal	I-NP	JJ	O	10	NMOD	0
9	neovascular	neovascular	I-NP	JJ	O	10	NMOD	0
10	membranes	membrane	I-NP	NNS	O	6	PMOD	0
11	associated	associate	B-VP	VBN	O	10	NMOD	0
12	with	with	B-PP	IN	O	11	VMOD	0
13	age-related	age-related	B-NP	JJ	O	15	NMOD	0
14	macular	macular	I-NP	JJ	O	15	NMOD	0
15	degeneration	degeneration	I-NP	NN	O	12	PMOD	6	degeneration
16	.	.	O	.	O	1	P	0

1	Photodynamic	Photodynamic	B-NP	JJ	O	2	NMOD	0
2	therapy	therapy	I-NP	NN	O	6	SUB	0
3	(	(	O	(	O	5	DEP	0
4	PDT	PDT	B-NP	NN	O	5	DEP	0
5	)	)	O	)	O	2	NMOD	0
6	is	be	B-VP	VBZ	O	0	ROOT	0
7	a	a	B-NP	DT	O	10	NMOD	0
8	novel	novel	I-NP	JJ	O	10	NMOD	0
9	treatment	treatment	I-NP	NN	O	10	NMOD	0
10	entity	entity	I-NP	NN	O	6	PRD	0
11	that	that	B-NP	WDT	O	10	NMOD	0
12	exploits	exploit	B-VP	VBZ	O	11	SBAR	0
13	the	the	B-NP	DT	O	15	NMOD	0
14	photophysical	photophysical	I-NP	JJ	O	15	NMOD	0
15	properties	property	I-NP	NNS	O	12	OBJ	0
16	of	of	B-PP	IN	O	15	NMOD	0
17	various	various	B-NP	JJ	O	20	NMOD	0
18	photosensitive	photosensitive	I-NP	JJ	O	20	NMOD	0
19	chemical	chemical	I-NP	NN	O	20	NMOD	0
20	entities	entity	I-NP	NNS	O	16	PMOD	0
21	which	which	B-NP	WDT	O	20	NMOD	0
22	,	,	O	,	O	21	P	0
23	upon	upon	B-PP	IN	O	27	VMOD	0
24	light	light	B-NP	JJ	O	25	NMOD	0
25	activation	activation	I-NP	NN	O	23	PMOD	0
26	,	,	O	,	O	27	P	0
27	results	result	B-VP	VBZ	O	21	SBAR	0
28	in	in	B-PP	IN	O	27	VMOD	0
29	targeted	target	B-NP	VBN	O	30	NMOD	0
30	photooxidation	photooxidation	I-NP	NN	O	34	NMOD	0
31	and	and	O	CC	O	34	NMOD	0
32	subsequent	subsequent	B-NP	JJ	O	34	NMOD	0
33	tissue	tissue	I-NP	NN	O	34	NMOD	0
34	destruction	destruction	I-NP	NN	O	28	PMOD	6	destruction
35	.	.	O	.	O	6	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	antiangiogenic	antiangiogenic	I-NP	JJ	O	3	NMOD	3	angiogenic
3	properties	property	I-NP	NNS	O	6	SUB	18	properties
4	of	of	B-PP	IN	O	3	NMOD	0
5	PDT	PDT	B-NP	NN	O	4	PMOD	0
6	have	have	B-VP	VBP	O	0	ROOT	0
7	been	be	I-VP	VBN	O	6	VC	0
8	adapted	adapt	I-VP	VBN	O	7	VC	0
9	for	for	B-PP	IN	O	8	VMOD	0
10	treatment	treatment	B-NP	NN	O	9	PMOD	19	treatment
11	of	of	B-PP	IN	O	10	NMOD	0
12	subfoveal	subfoveal	B-NP	JJ	O	14	AMOD	0
13	choroidal	choroidal	I-NP	JJ	O	14	AMOD	0
14	neovascular	neovascular	I-NP	JJ	O	15	NMOD	0
15	membranes	membrane	I-NP	NNS	O	11	PMOD	0
16	due	due	B-ADJP	JJ	O	17	PMOD	0
17	to	to	B-PP	TO	O	8	VMOD	0
18	disease	disease	B-NP	NN	O	19	NMOD	0
19	states	state	I-NP	NNS	O	17	PMOD	0
20	such	such	B-PP	JJ	O	21	PMOD	0
21	as	as	I-PP	IN	O	19	NMOD	0
22	age-related	age-related	B-NP	JJ	O	24	NMOD	0
23	macular	macular	I-NP	JJ	O	24	NMOD	0
24	degeneration	degeneration	I-NP	NN	O	21	PMOD	6	degeneration
25	(	(	O	(	O	27	DEP	0
26	AMD	AMD	B-NP	NN	O	27	DEP	0
27	)	)	O	)	O	24	NMOD	0
28	.	.	O	.	O	6	P	0

1	Historically	Historically	B-ADVP	RB	O	4	VMOD	0
2	,	,	O	,	O	4	P	0
3	PDT	PDT	B-NP	NN	O	4	SUB	0
4	has	have	B-VP	VBZ	O	0	ROOT	0
5	been	be	I-VP	VBN	O	4	VC	0
6	limited	limit	I-VP	VBN	O	5	VC	0
7	by	by	B-PP	IN	O	6	VMOD	0
8	a	a	B-NP	DT	O	9	NMOD	0
9	lack	lack	I-NP	NN	O	7	PMOD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	suitable	suitable	B-NP	JJ	O	13	NMOD	0
12	photosensitive	photosensitive	I-NP	JJ	O	13	NMOD	0
13	dyes	dye	I-NP	NNS	O	10	PMOD	0
14	.	.	O	.	O	4	P	0

1	However	However	B-ADVP	RB	O	13	VMOD	0
2	,	,	O	,	O	13	P	0
3	agents	agent	B-NP	NNS	O	13	SUB	0
4	such	such	B-PP	JJ	O	5	PMOD	0
5	as	as	I-PP	IN	O	3	NMOD	0
6	verteporfin	verteporfin	B-NP	NN	B-protein	11	NMOD	0
7	,	,	O	,	O	11	P	0
8	a	a	B-NP	DT	O	11	NMOD	0
9	second-generation	second-generation	I-NP	JJ	O	11	NMOD	0
10	benzoporphyrin	benzoporphyrin	I-NP	NN	O	11	NMOD	0
11	derivative	derivative	I-NP	NN	O	5	PMOD	0
12	,	,	O	,	O	3	P	0
13	appear	appear	B-VP	VBP	O	0	ROOT	0
14	to	to	I-VP	TO	O	15	VMOD	0
15	be	be	I-VP	VB	O	13	VMOD	0
16	free	free	B-ADJP	JJ	O	15	PRD	0
17	from	from	B-PP	IN	O	16	AMOD	0
18	the	the	B-NP	DT	O	20	NMOD	0
19	extensive	extensive	I-NP	JJ	O	20	NMOD	0
20	phototoxicity	phototoxicity	I-NP	NN	O	17	PMOD	0
21	that	that	B-NP	WDT	O	20	NMOD	0
22	limited	limit	B-VP	VBD	O	21	SBAR	0
23	the	the	B-NP	DT	O	24	NMOD	0
24	success	success	I-NP	NN	O	22	OBJ	0
25	of	of	B-PP	IN	O	24	NMOD	0
26	previous	previous	B-NP	JJ	O	27	NMOD	0
27	agents	agent	I-NP	NNS	O	25	PMOD	0
28	.	.	O	.	O	13	P	0

1	Verteporfin	Verteporfin	B-NP	NN	B-protein	2	SUB	0
2	has	have	B-VP	VBZ	O	0	ROOT	0
3	a	a	B-NP	DT	O	5	NMOD	0
4	high	high	I-NP	JJ	O	5	NMOD	0
5	affinity	affinity	I-NP	NN	O	2	OBJ	15	affinity
6	for	for	B-PP	IN	O	5	NMOD	0
7	choroidal	choroidal	B-NP	JJ	O	9	NMOD	0
8	neovascular	neovascular	I-NP	JJ	O	9	NMOD	0
9	membranes	membrane	I-NP	NNS	O	6	PMOD	0
10	,	,	O	,	O	5	P	0
11	typically	typically	B-VP	RB	O	12	VMOD	0
12	found	find	I-VP	VBN	O	5	NMOD	0
13	with	with	B-PP	IN	O	12	VMOD	0
14	exudative	exudative	B-NP	JJ	O	15	NMOD	0
15	AMD	AMD	I-NP	NN	O	13	PMOD	0
16	,	,	O	,	O	2	P	0
17	and	and	O	CC	O	2	VMOD	0
18	upon	upon	B-PP	IN	O	2	VMOD	0
19	photoactivation	photoactivation	B-NP	NN	O	18	PMOD	0
20	results	result	B-VP	VBZ	O	18	SBAR	17	results
21	in	in	B-PP	IN	O	20	VMOD	0
22	targeted	target	B-NP	VBN	O	27	NMOD	0
23	microvascular	microvascular	I-NP	JJ	O	24	NMOD	0
24	damage	damage	I-NP	NN	O	27	NMOD	6	damage
25	and	and	I-NP	CC	O	27	NMOD	0
26	thrombus	thrombus	I-NP	NN	O	27	NMOD	0
27	formation	formation	I-NP	NN	O	21	PMOD	2	formation
28	with	with	B-PP	IN	O	27	NMOD	0
29	resultant	resultant	B-NP	JJ	O	31	NMOD	0
30	vessel	vessel	I-NP	NN	O	31	NMOD	0
31	occlusion	occlusion	I-NP	NN	O	28	PMOD	0
32	.	.	O	.	O	2	P	0

1	Scrutiny	Scrutiny	B-NP	NN	O	20	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	diagnostic	diagnostic	B-NP	JJ	O	4	NMOD	0
4	indicators	indicator	I-NP	NNS	O	2	PMOD	0
5	for	for	B-PP	IN	O	1	NMOD	0
6	verteporfin	verteporfin	B-NP	NN	O	7	NMOD	0
7	administration	administration	I-NP	NN	O	5	PMOD	19	administration
8	,	,	O	,	O	1	P	0
9	including	include	B-PP	VBG	O	1	NMOD	0
10	critical	critical	B-NP	JJ	O	11	AMOD	0
11	angiographic	angiographic	I-NP	JJ	O	12	NMOD	0
12	evaluation	evaluation	I-NP	NN	O	18	NMOD	0
13	of	of	B-PP	IN	O	12	NMOD	0
14	lesion	lesion	B-NP	NN	O	15	NMOD	0
15	size	size	I-NP	NN	O	13	PMOD	0
16	and	and	O	CC	O	18	NMOD	0
17	visual	visual	B-NP	JJ	O	18	NMOD	0
18	acuity	acuity	I-NP	NN	O	9	PMOD	0
19	,	,	O	,	O	1	P	0
20	is	be	B-VP	VBZ	O	0	ROOT	0
21	essential	essential	B-ADJP	JJ	O	20	PRD	0
22	to	to	B-PP	TO	O	21	AMOD	0
23	treatment	treatment	B-NP	NN	O	24	NMOD	0
24	success	success	I-NP	NN	O	22	PMOD	0
25	.	.	O	.	O	20	P	0

1	Large	Large	B-NP	JJ	O	2	NMOD	0
2	lesions	lesion	I-NP	NNS	O	13	SUB	0
3	with	with	B-PP	IN	O	2	NMOD	0
4	relatively	relatively	B-NP	RB	O	5	AMOD	0
5	good	good	I-NP	JJ	O	7	NMOD	0
6	visual	visual	I-NP	JJ	O	7	NMOD	0
7	acuity	acuity	I-NP	NN	O	3	PMOD	0
8	(	(	O	(	O	12	DEP	0
9	20/50	20/50	B-NP	CD	O	12	DEP	0
10	or	or	O	CC	O	12	DEP	0
11	better	good	B-ADJP	JJR	O	12	DEP	0
12	)	)	O	)	O	7	NMOD	0
13	may	may	B-VP	MD	O	0	ROOT	0
14	be	be	I-VP	VB	O	13	VC	0
15	at	at	B-PP	IN	O	14	VMOD	0
16	particular	particular	B-NP	JJ	O	17	NMOD	0
17	risk	risk	I-NP	NN	O	15	PMOD	0
18	for	for	B-PP	IN	O	17	NMOD	0
19	marked	marked	B-NP	JJ	O	21	NMOD	0
20	vision	vision	I-NP	NN	O	21	NMOD	0
21	loss	loss	I-NP	NN	O	18	PMOD	0
22	following	follow	B-VP	VBG	O	21	NMOD	0
23	verteporfin	verteporfin	B-NP	NN	O	24	NMOD	0
24	administration	administration	I-NP	NN	O	22	OBJ	19	administration
25	.	.	O	.	O	13	P	0

1	Lesion	Lesion	B-NP	NN	O	2	NMOD	0
2	composition	composition	I-NP	NN	O	4	SUB	0
3	also	also	B-ADVP	RB	O	4	VMOD	0
4	appears	appear	B-VP	VBZ	O	0	ROOT	0
5	to	to	I-VP	TO	O	6	VMOD	0
6	influence	influence	I-VP	VB	O	4	VMOD	0
7	visual	visual	B-NP	JJ	O	8	NMOD	0
8	outcome	outcome	I-NP	NN	O	6	OBJ	0
9	with	with	B-PP	IN	O	6	VMOD	0
10	verteporfin	verteporfin	B-NP	NN	O	11	NMOD	0
11	use	use	I-NP	NN	O	9	PMOD	19	use
12	.	.	O	.	O	4	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	safety	safety	I-NP	NN	O	5	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	verteporfin	verteporfin	B-NP	NN	O	3	PMOD	0
5	is	be	B-VP	VBZ	O	0	ROOT	0
6	directly	directly	B-ADJP	RB	O	7	AMOD	0
7	dependent	dependent	I-ADJP	JJ	O	5	PRD	0
8	upon	upon	B-PP	IN	O	7	AMOD	0
9	the	the	B-NP	DT	O	11	NMOD	0
10	appropriate	appropriate	I-NP	JJ	O	11	NMOD	0
11	integration	integration	I-NP	NN	O	18	NMOD	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	dosage	dosage	B-NP	NN	O	12	PMOD	0
14	,	,	O	,	O	18	P	0
15	infusion	infusion	B-NP	NN	O	18	NMOD	0
16	and	and	O	CC	O	18	NMOD	0
17	light	light	B-NP	NN	O	18	NMOD	0
18	activation	activation	I-NP	NN	O	8	PMOD	0
19	required	require	B-VP	VBN	O	18	NMOD	0
20	for	for	B-PP	IN	O	19	VMOD	0
21	a	a	B-NP	DT	O	24	NMOD	0
22	suitable	suitable	I-NP	JJ	O	24	NMOD	0
23	pharmacotherapeutic	pharmacotherapeutic	I-NP	JJ	O	24	NMOD	0
24	outcome	outcome	I-NP	NN	O	20	PMOD	0
25	.	.	O	.	O	5	P	0

1	When	When	B-ADVP	WRB	O	24	VMOD	0
2	used	use	B-VP	VBN	O	1	SBAR	0
3	appropriately	appropriately	B-ADVP	RB	O	2	VMOD	0
4	,	,	O	,	O	24	P	0
5	and	and	O	CC	O	24	VMOD	0
6	with	with	B-PP	IN	O	24	SUB	0
7	adequate	adequate	B-NP	JJ	O	9	NMOD	0
8	patient	patient	I-NP	NN	O	9	NMOD	0
9	education	education	I-NP	NN	O	6	PMOD	0
10	regarding	regard	B-VP	VBG	O	9	NMOD	0
11	photosensitivity	photosensitivity	B-NP	NN	O	14	NMOD	0
12	,	,	O	,	O	14	P	0
13	the	the	B-NP	DT	O	14	NMOD	0
14	risk-benefit	risk-benefit	I-NP	NN	O	10	PMOD	0
15	of	of	B-PP	IN	O	14	NMOD	0
16	verteporfin	verteporfin	B-NP	NN	O	15	PMOD	0
17	for	for	B-PP	IN	O	14	NMOD	0
18	the	the	B-NP	DT	O	20	NMOD	0
19	medical	medical	I-NP	JJ	O	20	NMOD	0
20	treatment	treatment	I-NP	NN	O	17	PMOD	19	treatment
21	of	of	B-PP	IN	O	20	NMOD	0
22	neovascular	neovascular	B-NP	JJ	O	23	NMOD	0
23	AMD	AMD	I-NP	NN	O	21	PMOD	0
24	is	be	B-VP	VBZ	O	0	ROOT	0
25	favourable	favourable	B-ADJP	JJ	O	24	PRD	0
26	.	.	O	.	O	24	P	0

